MiddleBrook Pharmaceuticals Inc
MiddleBrook Pharmaceuticals — Q3 2009 Earnings Presentation
10 slides from MiddleBrook Pharmaceuticals's earnings presentation, Nov 5, 2009
Slide 1: MiddleBrook Pharmaceuticals, Inc. Third Quarter 2009 Conference Call Slides
MiddleBrook Pharmaceuticals, Inc. Third Quarter 2009 Conference Call Slides
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about MiddleBrook's strategies for the commercialization of MOXATAG, MOXATAG's expected growth and market position,
Slide 3: Pharmacy Stocking Survey Data (CATS / Synergistix)
Source: MiddleBrook Pharmacy Stocking Survey Data from the Customer Analysis & Targeting System (CATS) / Synergistix, Inc. 3
Slide 4: Moxatag Weekly Prescriptions
4 July 14: $20 max co-pay program began Moxatag Weekly Prescriptions Source: IMS Health(tm) Xponent weekly data for the week ended 10/23/2009
Slide 5: Weekly Data for the week ended 10/16/2009
Source: IMS Health(tm) Xponent Weekly Data for the week ended 10/16/2009 5
Slide 6: Monthly data for the month ended August 2009
6 Source: IMS Health(tm) Xponent monthly data for the month ended August 2009
Slide 7: $1 Billion Market Opportunity in Antibiotic Class 7
16.4 million oral-solid pharyngitis TRx in 2008 Antibiotic Class 7 $1 Billion Market Opportunity Note: The source for the prescription data is the IMS Health National Prescription Audit(tm) and National Disease and Therapeutic Index(tm) 2008 ,and the dollar market opportunity is calculated at our ex
Slide 8: Weekly data for the week ended 10/16/2009
Source: IMS Health(tm) Xponent weekly data for the week ended 10/16/2009 8
Slide 9: Physicians Rate Moxatag Favorably Compared to Amoxicillin
Physicians Rate Moxatag Favorably Compared to Amoxicillin Survey of U.S. PCPs: Average rating of Moxatag vs. generic amoxicillin Dosing frequency Likely compliance Efficacy Side effect profile Past success Duration of therapy Very poor Very good Once-daily dosing is cited as the most attractive feat
Slide 10: Trademarks notice
KEFLEX, KEFLEX 250 MG, KEFLEX 500MG, KEFLEX 750 MG, MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., M1 (stylized), MOX-10, MOXAKIT, MOXATAG1 (stylized), MOXATAG, MOXATEN, MOXPAK, MOX-PAK and PULSYS are our trademarks and have been registered in the U.S. Patent
MiddleBrook Pharmaceuticals — Q3 2009 Earnings Presentation on 6ix